NCT05717153View on ClinicalTrials.gov

Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

January 15, 2027

Study Completion Date

September 15, 2027

Conditions
Diffuse GliomaMalignant Glioma
Interventions
PROCEDURE

Biospecimen Collection

Undergo collection of blood

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Eflornithine

Given PO

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Polyamine Transport Inhibitor AMXT-1501 Dicaprate

Given PO

PROCEDURE

Resection

Undergo surgical resection

DEVICE

Microdialysis

Undergo Microdialysis

PROCEDURE

Placement

Undergo placement of catheters

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT05717153 - Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma | Biotech Hunter | Biotech Hunter